



THIS NEW CLASS OF DIAGNOSTIC TESTING — LIQUID BIOPSY — IS ENABLING OUR UNDERSTANDING OF THE GENOMIC LANDSCAPE AND FUNCTIONALITY OF CANCER AS WELL AS DEVELOPING ENHANCED PRECISION MEDICINE APPROACHES TO PATIENT TREATMENT AND MANAGEMENT.

PlasmaDx Monitoring™ is a collection of ctDNA tests from the AVENIO ctDNA Assay Portfolio (Roche Sequencing Systems) validated for use in our PacificDx CAP/CLIA laboratory. PlasmaDx Monitoring covers a variety of clinical oncology research scenarios and provides support for biopharmaceutical clinical trials.

TESTING

- 5 day turn-around-time (TAT)
- High (> 90% sensitivity) at low $\geq 0.5\%$ allele frequencies
- Broad coverage across tumor types

CLINICAL FEATURES

Each assay provides information about the status of clinically-actionable genomic alterations (SNVs, indels, fusions, CNAs) including those targeted by FDA-approved therapeutics. A matched tissue/plasma testing option is also available.

Our Lab is Your Lab™

Our fully accredited and licensed clinical molecular laboratory, PacificDx, is a wholly owned subsidiary of ResearchDx. As a premier CLIA, CAP and ISO laboratory, our reputation is solidly built on our technical capabilities, quality and rapid turnaround of test results.

PacificDx provides an extensive array of clinical, esoteric and consulting laboratory services to biopharmaceutical and clinical diagnostics laboratories, as well as serving as a discrete laboratory testing resource for medical professionals.

Our capabilities include a menu of liquid biopsy and solid tumor-based molecular and non-molecular technologies that meet the growing demands for understanding the genomic landscape and functionality of cancer in precision medicine.

PlasmaDx Monitoring Options

PlasmaDx Targeted

- Analyzes hotspot areas of 17 cancer-related genes
- Optimized for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC)
- Applicable for pan-cancer applications
- Best choice for on-label therapeutic decision-making or plasma monitoring of tumors with known EGFR, KRAS, BRAF genomic alterations

PlasmaDx Expanded

- Analyzes hotspot areas of 77 cancer-related genes
- Optimized for NSCLC and CRC with expanded gene list and hotspot coverage
- Applicable for plasma monitoring of tumor burden and identification of targetable genomic alterations
- Best choice for higher coverage for pan-cancer applications and biomarker discovery

PlasmaDx Surveillance

- Analyzes hotspot and whole exon targets of 197 cancer-related genes
- Includes guideline driven and emerging tumor biomarkers for therapeutic decision making
- Applicable for longitudinal monitoring of tumor burden and identification of targetable genomic alterations.
- Best choice for detecting a patient's cancer personalized profile by deep sequencing (CAPP-Seq)

PlasmaDx Matched

- Analyzes matched tissue DNA and ctDNA from plasma simultaneously using PlasmaDx's Targeted, Expanded, or Surveillance tests at the time of diagnosis, recurrence, and metastases
- Applicable for small high grade tumors at the time of diagnosis and pre/post-surgery tumor burden monitoring
- Best choice for biomarker identification in tissue followed by monitoring in plasma ctDNA